Monoclonal Antibodies: A Review

Title:Monoclonal Antibodies: A Review

Volume: 13 Issue: 2

Author(s): Surjit Singh*, Nitish K. Tank, Pradeep Dwiwedi, Jaykaran Charan, Rimplejeet Kaur, Preeti Sidhu and Vinay K. Chugh

Affiliation:

• Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan 342005,India

Keywords: Monoclonal antibody, cancer, autoimmune, transplant, cytokines, growth factors.

Abstract: Background: Over the last three decades, monoclonal antibodies (MAbs) have made a striking transformation from scientific tools to powerful human therapeutics. Muromonab CD3 a murine MAb was the first FDA approved therapeutic MAb for the prevention of kidney transplant rejection. Since its approval in 1986, there has been a decline in further application and approvals until the late 1990s when the first chimeric Mab, Rituximab was approved for the treatment of lowgrade B cell lymphoma in 1997. With the approval by licensing authorities of chimeric, followed by humanized and then fully human monoclonal antibodies, the rate of approval and monoclonal antibodies available in the market for the treatment of various diseases has increased dramatically. As of March 2017, FDA has approved approximately 60 therapeutic MAbs which are currently under evaluation in various phases of clinical trials.

Objective: MAbs are approved for the treatment of diseases belonging to various systems like cardiovascular, respiratory, hematology, kidney, immunology and oncology. MAbs are approved for the treatment of orphan diseases or indications such as paroxysmal nocturnal hemoglobinuria as well as cancers and multiple sclerosis where hundreds of patients are treated and even diseases such as breast cancer, asthma and rheumatoid arthritis where millions are being treated. This review focuses briefly on types, molecular targets, mechanism of actions and therapeutic indications of FDA approved MAb products that are currently available in the market.

Conclusion: With the advent of fully human MAbs, the efficacy and safety have improved in the treatment of various cardiovascular, cancer, respiratory, hematology, autoimmune diseases and infections. The introduction of biosimilars will increase the affordability and utilization of MAbs in the treatment of various diseases.

Cite this article as:

Singh Surjit *, Tank K. Nitish , Dwiwedi Pradeep , Charan Jaykaran , Kaur Rimplejeet , Sidhu Preeti and Chugh K. Vinay, Monoclonal Antibodies: A Review, Current Clinical Pharmacology 2018; 13 (2) . https://dx.doi.org/10.2174/1574884712666170809124728